mecasermin rinfabate
Preclinical
Novo Nordiskmecasermin rinfabate is one of 30 therapeutic programs targeting Growth. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
364 competitors in Growth
#DrugCompanyPhaseTrials
1Genotropin
EMD SeronoPreclinical
Lovenox
SanofiPreclinical
Aricept
EisaiPreclinical
Zolymbus
AbbViePreclinical
Herceptin
OOrganon and Co
Preclinical
Somavaratan
Novo NordiskPreclinical
Glucophage
EMD SeronoPreclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Preclinical
Glucagon
XXeris Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mecasermin rinfabate. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company